Medical Device Industry Latest News Report (April 8, 2026)

Introduction

We have compiled major domestic and international news regarding the latest trends in the medical device industry. We cover a wide range of topics, from new product approvals and M&A to supply chain challenges and notable AI and robotic technologies.

1. Notable M&A and Industry Restructuring Trends

The medical device and healthcare industries are actively engaged in large-scale M&A and spin-offs to optimize business portfolios and acquire new technologies.

Blackstone and TPG Complete Acquisition of Hologic

On April 7, 2026, investment funds Blackstone and TPG completed the acquisition of Hologic, a global leader in women's health. The total transaction value amounted to approximately $17.2 billion (up to $79 per share). With this acquisition, Hologic has become a private company, and José (Joe) E. Almeida has been appointed as the new CEO.

Impact on the Industry: This large-scale acquisition of a medical device manufacturer by private equity (PE) funds symbolizes the restructuring of the market. By going private, Hologic is expected to be able to make long-term investments in innovation without being constrained by short-term market pressures.

MiniMed Carve-out IPO by Medtronic

Medtronic partially spun off its diabetes business unit (MiniMed) and completed an initial public offering (IPO) on the NASDAQ market in March 2026 (ticker symbol: MMED). Medtronic remains the largest shareholder, retaining approximately 90% of the shares after the IPO, making this a carve-out listing rather than a complete spin-off. MiniMed provides advanced devices such as insulin pumps and continuous glucose monitoring (CGM).

Impact on the Industry: This is a typical example of "selection and concentration" by a major medical device manufacturer. While Medtronic focuses its investments on growth areas, the independent MiniMed is expected to increase agility in the diabetes care market and accelerate product development speed.

2. New Products/Technological Innovations (AI, Robotics, Digital Health)

The implementation of AI (Artificial Intelligence) and robotics technology in medical devices is progressing at an unprecedented speed.

NVIDIA Unveils VLA "GR00T-H" for Surgical Assistance Robots

At the "GTC" developer conference held in March 2026, NVIDIA announced "GR00T-H," a new AI foundation model specifically for the medical industry. This is a VLA (Vision-Language-Action) model for surgical assistance robots that can generate robotic actions such as suturing when given image and text instructions.

Impact on the Industry: This technology significantly advances the introduction of "Physical AI" into medical settings. It opens the door to a future where robots, which previously only assisted doctors' operations, autonomously judge situations and act, directly leading to improved precision in surgical operations and reduced burden on doctors.

Fujifilm Launches New Model of AI-Equipped X-Ray Fluoroscopy System

Fujifilm has launched a new model of its digital X-ray fluoroscopy system utilizing AI technology. It is equipped with a function that detects the examination/treatment area and the patient's movement using AI, thereby reducing the amount of medication administered and alleviating the patient's physical burden.

Impact on the Industry: AI utilization in the field of diagnostic imaging is evolving from "diagnostic support" to "optimization of imaging and examination processes." This is a good example of achieving both improved patient safety and improved workflow for healthcare professionals.

3. Regulatory Trends and New Product Approvals

Regulatory authorities both domestically and internationally (FDA and PMDA) are accelerating the market introduction of new medical technologies while establishing frameworks to ensure safety.

VDYNE's tricuspid valve replacement system receives FDA IDE approval

U.S. company VDYNE has received FDA (U.S. Food and Drug Administration) approval to begin a pivotal trial (TRIVITA1 IDE) for its investigational transcatheter tricuspid valve replacement (TTVR) system.

Impact on the industry: This could expand the options for minimally invasive treatments for tricuspid regurgitation. The structural heart disease field is currently one of the most important markets, with medical device manufacturers fiercely competing in development.

Nagoya University, Okayama University, and Menicon's absorbable bone regeneration material "Verte" approved

Verte, an absorbable bone regeneration material developed through a collaborative research effort by Nagoya University, Okayama University, and Menicon Co., Ltd., received medical device approval in Japan in February 2026. It is a bone substitute material using self-assembling peptide gel technology.

Impact on the industry: This is an innovative domestic material that improves intraoperative operability and promotes early bone fusion after surgery in bone defect reconstruction. It is noteworthy as a successful example of industry-academia collaboration in medical device development.

Terumo's radiofrequency ablation system "arfa" expands indications

Terumo's radiofrequency ablation system "arfa" has expanded its indications from conventional liver cancer to include lung cancer, small renal cancer, and bone metastases, and was covered by insurance on April 1, 2026.

Impact on the industry: By expanding the scope of minimally invasive cancer treatment (treatment that places less burden on the patient's body compared to surgical resection), it is expected to contribute to improving the QOL (quality of life) of more patients.

4. Supply Chain and Policy Challenges

Geopolitical risks and inflation are casting a shadow over the stable supply of medical devices.

Concerns about Medical Device Shipments Due to Naphtha Shortage

Due to the deteriorating situation in the Middle East, the shortage of "naphtha," a basic raw material for plastics and synthetic rubber, is becoming severe. There are concerns that some medical devices, such as disposable medical instruments used for artificial dialysis and surgery, may become difficult to ship domestically from April to August.

Impact on the Industry: This is a critical issue directly linked to maintaining the functionality of medical sites. Strengthening supply chains, developing alternative materials that do not depend on specific regions or raw materials, and promoting recycling technologies are urgent tasks for the entire industry.

AMDD's Recommendations for "Basic Policy 2026"

The American Medical Devices and IVD Industry Association (AMDD) has submitted recommendations for the Japanese government's "Basic Policy on Economic and Fiscal Management and Reform 2026." They are calling for flexible insurance reimbursement prices in response to inflation and other factors, and the promotion of international harmonization of pharmaceutical regulations to resolve device lag.

Impact on the Industry: Amid rising prices, the "negative spread" problem, where medical device manufacturers and medical institutions cannot absorb cost increases with current insurance reimbursement prices, has become apparent. There is a strong demand for the introduction of a flexible pricing system to avoid hindering innovation.

Summary

As of April 2026, the medical device industry is being driven by "technological breakthroughs through AI and robotics" and "business reorganization through M&A," while simultaneously facing practical challenges such as "supply chain vulnerabilities" and "limitations of the pricing system under inflation." Moving forward, how companies overcome these challenges and how quickly and safely they can deliver the latest technologies to patients will likely determine their competitiveness in the industry.